StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
2677.HK$22.28+2.86%
Fair $22.28+0.0%

2677.HK

Distinct Healthcare Hldg Ltd

Healthcare / Medical Care FacilitiesHKSE

$22.28

+0.62 (+2.86%)

Fairly Valued+0.0%Fair Value $22.28Fund rank 30/100 · Data gapFallback financials|
SA 46/C
F-Score: 6/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 32% · confianza 23%

FCF escenarios

weak_data · normalized FCF $111.9M · quality 51.3/100

Data gap 30/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 33/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

46/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -8.3%, below the 5% threshold
Thesis & Journal · 2677.HKLocal privado en este navegador · Distinct Healthcare Hldg Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.4B

P/E

8.9x

↓

EV/EBITDA

5.0x

↓

ROE

-8.3%

↓

Gross Margin

25.1%

↓

Debt/Equity

-0.18

↓
52-Week Range$22
$20$91

TradingView lightweight chart

2677.HK price, volumen y niveles de valoración

Último $22.28Periodo -67.2%
Fair value: $22.28

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+31.0%

FCF CAGR

—

FCF margin

13.7%

FCF / Net income

1.08x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.06B · net income $135.1M · FCF $145.8M

2022-FY → 2025-FY

Gross margin

25.1%+15.8% pts

Operating margin

2.9%+34.8% pts

Net margin

12.7%+58.2% pts

FCF margin

13.7%+31.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.06B$1.06B$958.6M$690.4M$473.2M
Net Income$135.1M$135.1M$83.8M$-350.7M$-215.5M
EBITDA$281.4M$281.4M$232.2M$-219.1M$-112.7M
EPS——1.30-5.45-3.35
Gross Margin25.1%25.1%23.6%19.3%9.3%
Operating Margin2.9%2.9%-5.5%-8.0%-31.9%
Net Margin12.7%12.7%8.7%-50.8%-45.5%
Balance Sheet
Debt/Equity-0.18-0.18-0.19-0.18-0.22
Current Ratio0.250.25———
Cash Flow
Free Cash Flow$145.8M$145.8M$111.9M$55.7M$-83.4M
Returns
ROE-8.3%-8.3%-4.7%19.9%15.3%
Valuation
P/E8.958.95———
EV/EBITDA4.974.97———
Growth & Yield
Revenue Growth11.1%11.1%38.8%45.9%—
EPS Growth——123.9%-62.7%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total -67.2%

Total return

-67.2%

Start / end P/E

n/dx → n/dx

EPS bridge

1.30 → n/d

Residual

-67.2%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-67.2%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.